{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"RLYB","limit":50},"count":50,"signals":[{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":"gress the development of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of these product candidates;Enrollment and retention of patients in rare disease clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control","filed_date":"2026-03-16","accession":"0001628280-26-018261","full_text":"https://origin.rootz.global/static/filing/0001628280-26-018261.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":61,"context":"completing, the proposed Merger with Candid could materially and adversely affect our results of operations, business, financial results and/or stock price; The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes and/or other causes;iiTable of Contents Our stockholders may not realize a benefit from the Merger commensurate with the ownershi","filed_date":"2026-03-16","accession":"0001628280-26-018261","full_text":"https://origin.rootz.global/static/filing/0001628280-26-018261.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":47,"context":"ial that demonstrated an inability of the RLYB212 dose regimen to achieve predicted target concentrations, as well as the minimum target concentration required for efficacy. In July 2025, the Company entered into a definitive agreement to sell its interest in REV102, an Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (\"ENPP1\") inhibitor in preclinical development for the treatment of patients with hypophosphatasia (\"HPP\"), to a","filed_date":"2026-03-16","accession":"0001628280-26-018261","full_text":"https://origin.rootz.global/static/filing/0001628280-26-018261.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2025-11-06","accession":"0001739410-25-000132","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000132.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2025-08-07","accession":"0001739410-25-000112","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2025-05-08","accession":"0001739410-25-000061","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"024, Drs. Mackay and Uden were granted an option to purchase 216,000 shares of our common stock under the Rallybio Corporation 2021 Equity Incentive Plan (the 2021 Plan), which vests in 48 equal installments over four years. In fiscal year 2024, Mr. Lieber and Dr. Ryder were granted an option to purchase 120,000 shares of our common stock under the 2021 Plan, which vests in 48 equal installments over","filed_date":"2025-04-07","accession":"0001739410-25-000045","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":42,"context":"rposes of determining whether a quorum is present for the transaction of business at the meeting. What vote is required to approve each item Proposal 1 Elect Directors A nominee for director shall be elected to the Board of Directors if the votes properly cast FOR such nominees election exceed the votes properly cast AGAINST such nominees election (with abstentions and broker non-votes not counted as votes cast either FOR or AGA","filed_date":"2025-04-07","accession":"0001739410-25-000045","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ign and implement, and involve uncertain outcomes. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of our product candidates;Enrollment and retention of patients in rare disease clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control","filed_date":"2025-03-13","accession":"0001739410-25-000040","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"tdown occurs, or if the U.S. government takes other personnel actions, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Even if we obtain marketing approval for a product candidate in the United States, we or our current or future collaborators may never obtain approval for or commercialize the produ","filed_date":"2025-03-13","accession":"0001739410-25-000040","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2024-11-07","accession":"0001739410-24-000136","full_text":"https://origin.rootz.global/static/filing/0001739410-24-000136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2024-08-08","accession":"0001739410-24-000115","full_text":"https://origin.rootz.global/static/filing/0001739410-24-000115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"trictions with respect to the Companys securities. *Lien* means any lien, charge, claim, encumbrance, security interest, right of first refusal, preemptive right or other restrictions of any kind. *Material Adverse Effect* means a material adverse effect on the results of operations, assets, business or financial condition of the Company and the Subsidiaries, taken as a whole, except that any of the following, either","filed_date":"2024-05-10","accession":"0001193125-24-136133","full_text":"https://origin.rootz.global/static/filing/0001193125-24-136133.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2024-05-09","accession":"0001739410-24-000057","full_text":"https://origin.rootz.global/static/filing/0001739410-24-000057.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"023, Drs. Mackay and Uden were granted an option to purchase 214,000 shares of our common stock under the Rallybio Corporation 2021 Equity Incentive Plan (the 2021 Plan), which vests in 48 equal installments over four years. In connection with Mr. Lieber's appointment as Chief Financial Officer, in 2023, Mr. Lieber was granted an option to purchase 240,000 shares of our common stock under the 2021 Pl","filed_date":"2024-04-11","accession":"0001739410-24-000045","full_text":"https://origin.rootz.global/static/filing/0001739410-24-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":46,"context":"rposes of determining whether a quorum is present for the transaction of business at the meeting. What vote is required to approve each item Proposal 1 Elect Directors A nominee for director shall be elected to the Board of Directors if the votes properly cast FOR such nominees election exceed the votes properly cast AGAINST such nominees election (with abstentions and broker non-votes not counted as votes cast either FOR or AGA","filed_date":"2024-04-11","accession":"0001739410-24-000045","full_text":"https://origin.rootz.global/static/filing/0001739410-24-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":54,"context":"d stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Even if we obtain FDA approval for a product candidate in the United States, we or our current or future collaborators may never obtain approval for or commercialize the product can","filed_date":"2024-03-12","accession":"0001739410-24-000035","full_text":"https://origin.rootz.global/static/filing/0001739410-24-000035.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2023-11-09","accession":"0001739410-23-000014","full_text":"https://origin.rootz.global/static/filing/0001739410-23-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2023-08-08","accession":"0001739410-23-000007","full_text":"https://origin.rootz.global/static/filing/0001739410-23-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2023-05-09","accession":"0000950170-23-019165","full_text":"https://origin.rootz.global/static/filing/0000950170-23-019165.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":33,"context":"of determining whether a quorum is present for the transaction of business at the meeting. -5- What vote is required to approve each item? Proposal 1: Elect Directors: A nominee for director shall be elected to the Board of Directors if the votes properly cast FOR such nominee’s election exceed the votes properly cast AGAINST such nominee’s election (with “abstentions” and “broker non-votes","filed_date":"2023-04-10","accession":"0000950170-23-012313","full_text":"https://origin.rootz.global/static/filing/0000950170-23-012313.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":37,"context":"ize our product candidates. ▪ Manufacturing and supply: We have encountered only limited disruptions to our manufacturing and supply chain as a result of COVID-19 to date, which have not had a material adverse impact on our business, but significant or prolonged disruptions could materially impact our business, operations or financial results. Even if our manufacturing operations are not materially disrupted, pan","filed_date":"2023-03-06","accession":"0000950170-23-006264","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2022-11-07","accession":"0000950170-22-022342","full_text":"https://origin.rootz.global/static/filing/0000950170-22-022342.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2022-08-08","accession":"0000950170-22-015571","full_text":"https://origin.rootz.global/static/filing/0000950170-22-015571.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2022-05-10","accession":"0000950170-22-009013","full_text":"https://origin.rootz.global/static/filing/0000950170-22-009013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":28,"context":"ses of determining whether a quorum is present for the transaction of business at the meeting. What vote is required to approve each item? Proposal 1: Elect Directors: A nominee for director shall be elected to the Board of Directors if the votes properly cast FOR such nominee’s election exceed the votes properly cast AGAINST such nominee’s election (with “abstentions” and “broker non-votes","filed_date":"2022-04-25","accession":"0000950170-22-006110","full_text":"https://origin.rootz.global/static/filing/0000950170-22-006110.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":37,"context":"ize our product candidates. ▪ Manufacturing and supply: We have encountered only limited disruptions to our manufacturing and supply chain as a result of COVID-19 to date, which have not had a material adverse impact on our business, but significant or prolonged disruptions could materially impact our business, operations or financial results. Even if our manufacturing operations are not materially disrupted, pan","filed_date":"2022-03-15","accession":"0000950170-22-003767","full_text":"https://origin.rootz.global/static/filing/0000950170-22-003767.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2021-11-10","accession":"0000950170-21-004125","full_text":"https://origin.rootz.global/static/filing/0000950170-21-004125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"me, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, divers","filed_date":"2021-09-09","accession":"0000950170-21-001740","full_text":"https://origin.rootz.global/static/filing/0000950170-21-001740.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"Contents | | may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; | | | | | | Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2021-07-22","accession":"0001193125-21-221832","full_text":"https://origin.rootz.global/static/filing/0001193125-21-221832.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":37,"context":"product candidates. | | | | | | Manufacturing and supply: We have encountered only limited disruptions to our manufacturing and supply chain as a result of COVID-19 to date, which have not had a material adverse impact on our business, but significant or prolonged disruptions could materially impact our business, operations or financial results. Even if our manufacturing operations are not materially disrupted, pan","filed_date":"2021-07-22","accession":"0001193125-21-221832","full_text":"https://origin.rootz.global/static/filing/0001193125-21-221832.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":30,"context":"ast one major European market, we decide not to pursue any further development or commercialization activities for such products, then Prophylix will have the right to repurchase the remaining assets acquired under the agreement for approximately $1.2 million. Prophylix also will have the right to repurchase the remaining assets acquired under the agreement for approximately $1.2 million if we elect to transfer all or substantially all of the a","filed_date":"2021-07-22","accession":"0001193125-21-221832","full_text":"https://origin.rootz.global/static/filing/0001193125-21-221832.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"Contents | | may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; | | | | | | Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2021-07-02","accession":"0001193125-21-207662","full_text":"https://origin.rootz.global/static/filing/0001193125-21-207662.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":37,"context":"product candidates. | | | | | | Manufacturing and supply: We have encountered only limited disruptions to our manufacturing and supply chain as a result of COVID-19 to date, which have not had a material adverse impact on our business, but significant or prolonged disruptions could materially impact our business, operations or financial results. Even if our manufacturing operations are not materially disrupted, pan","filed_date":"2021-07-02","accession":"0001193125-21-207662","full_text":"https://origin.rootz.global/static/filing/0001193125-21-207662.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":28,"context":"ast one major European market, we decide not to pursue any further development or commercialization activities for such products, then Prophylix will have the right to repurchase the remaining assets acquired under the agreement for approximately $1.2 million. Prophylix also will have the right to repurchase the remaining assets acquired under the agreement for approximately $1.2 million if we elect to transfer all or substantially all of the a","filed_date":"2021-07-02","accession":"0001193125-21-207662","full_text":"https://origin.rootz.global/static/filing/0001193125-21-207662.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"completing, the proposed Merger with Avenzo could materially and adversely affect our results of operations, business, financial results and/or stock price; The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes and/or other causes; 4 [Table of Contents](#i4f5ce7b5b6f34fcc82f7c1d8a8430a5a_7) Our stockholders may not realize a benefit from","filed_date":"2026-08-06","accession":"0001628280-26-053880","full_text":"https://origin.rootz.global/static/filing/0001628280-26-053880.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"gn and implement, and involve uncertain outcomes. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of our product candidates; Enrollment and retention of patients in rare disease clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control","filed_date":"2025-11-06","accession":"0001739410-25-000132","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000132.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"gn and implement, and involve uncertain outcomes. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of our product candidates; Enrollment and retention of patients in rare disease clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control","filed_date":"2025-08-07","accession":"0001739410-25-000112","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"gn and implement, and involve uncertain outcomes. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of our product candidates; Enrollment and retention of patients in rare disease clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control","filed_date":"2025-05-08","accession":"0001739410-25-000061","full_text":"https://origin.rootz.global/static/filing/0001739410-25-000061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"receive marketing approval. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2024-11-07","accession":"0001739410-24-000136","full_text":"https://origin.rootz.global/static/filing/0001739410-24-000136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"receive marketing approval. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2024-08-08","accession":"0001739410-24-000115","full_text":"https://origin.rootz.global/static/filing/0001739410-24-000115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"eting approval. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; ii  Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2021-09-09","accession":"0000950170-21-001740","full_text":"https://origin.rootz.global/static/filing/0000950170-21-001740.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":73,"match_count":1,"context":"me, the Company estimates the efforts needed to complete the performance obligations and recognizes revenue over the satisfaction of the performance obligations. RestructuringThe Company accounts for restructuring charges in accordance with ASC Subtopic 420-10, Exit or Disposal Cost Obligations. The charges related to the workforce reduction are cash-based expenditures related primarily to severance and benefit paymen","filed_date":"2024-11-07","accession":"0001739410-24-000136","full_text":"https://origin.rootz.global/static/filing/0001739410-24-000136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"Mackay and Uden and Mr. Fryer received an option to purchase 62,000 shares of our common stock under the Rallybio Corporation 2021 Equity Incentive Plan (the 2021 Plan), which vests in 48 equal installments over four years, generally subject to the named executive officer’s continued employment with us through the applicable vesting date. -25- Outstanding equity awards at December 31, 2022 Th","filed_date":"2023-04-10","accession":"0000950170-23-012313","full_text":"https://origin.rootz.global/static/filing/0000950170-23-012313.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"eting approval. We may 4 incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; • Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2022-11-07","accession":"0000950170-22-022342","full_text":"https://origin.rootz.global/static/filing/0000950170-22-022342.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"eting approval. We may 4 incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; • Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2022-08-08","accession":"0000950170-22-015571","full_text":"https://origin.rootz.global/static/filing/0000950170-22-015571.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"eting approval. We may 4 incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; • Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2022-05-10","accession":"0000950170-22-009013","full_text":"https://origin.rootz.global/static/filing/0000950170-22-009013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":", each of our named executive officers received an award of 2,255,000 incentive units under the 2018 Plan, which vest as to 25% of the underlying units on January 1, 2022 and in 36 equal monthly installments thereafter, generally subject to the executive officer’s continued employment with us through the applicable vesting date. In connection with the liquidation of Rallybio Holdings LLC (Hold","filed_date":"2022-04-25","accession":"0000950170-22-006110","full_text":"https://origin.rootz.global/static/filing/0000950170-22-006110.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"eting approval. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; ii • Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2022-03-15","accession":"0000950170-22-003767","full_text":"https://origin.rootz.global/static/filing/0000950170-22-003767.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RLYB","company":"Rallybio Corp","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"eting approval. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; ii  Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including o","filed_date":"2021-11-10","accession":"0000950170-21-004125","full_text":"https://origin.rootz.global/static/filing/0000950170-21-004125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"9b0b73a6c068f454282715309bd1401c1ea0f003e6d5e444a32bbc80c5416ad8","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f1b0750d87c69f41c0595abbdab5bc4e503049a502c53951bb012f36644216e8","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":51,"hourly_limit":500,"remaining":449,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}